TAK-881

Phase 3Biologic

TAK-881 is one of 12 biologic programs targeting Chronic Inflammatory Demyelinating Polyradiculoneuropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyradiculoneuropathyRecruiting

Immunodeficiency DiseaseCompleted

Chronic Inflammatory Demyelinating PolyradiculoneuropathyPhase 3

Recruiting

Immunodeficiency DiseasePhase 3

Completed

Competition

Competitive Landscape

7 competitors in Immunodeficiency Disease

#DrugCompanyPhaseTrials

Famvir

Novartis

Approved

—2

Epivir

GGlaxo Dba Glaxosmithkline

Retrovir

Sustiva

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

TAK-881

2 6

Ziagen

Other

1 8

Bivigam

AADMA Biologics, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NCT06747351

Q1 2029

Phase 3Recruiting

Immunodeficiency Disease

NCT06076642

Clinical

Trials by Indication[1]

Adult2 trials

A Study of TAK-881 in Healthy Adults

Completed· Takeda logo

Takeda·Phase 1·NCT05059977·24 enrolled

A Study of TAK-881 and HyQvia in Healthy Adults

Completed· Takeda logo

Takeda·Phase 1·NCT06895967·30 enrolled

Immunodeficiency Disease2 trials

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Recruiting· Takeda logo

Takeda·Phase 3·NCT06076642·39 enrolled

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Completed· Takeda logo

Takeda·Phase 2/3·NCT05755035·65 enrolled

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1 trial

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Recruiting· Takeda logo

Takeda·Phase 3·NCT06747351·59 enrolled

Primary Immunodeficiency Diseases1 trial

Expanded Access Program for United States of America: TAK-881 Subcutaneous for the Treatment of Primary Immunodeficiency Diseases (PIDD); Specific Therapeutic Program for Czech Republic: TAK-881 Subcutaneous for the Treatment of Primary Immunodeficiency Diseases (PIDD)

Available· Takeda logo

Takeda··NCT06955793

Unspecified1 trial

A Phase 1, Open-Label, Within-Dose-Level Randomized Trial to Assess the Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous 20% (Human) With Recombinant Human Hyaluronidase (TAK-881) With Ramp-Up and No Ramp-Up Dosing in Healthy Adult Participants

Completed· Takeda logo

Takeda·Phase 1·NCT06935266·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for TAK-881. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAK-881 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAK-881. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Takeda

TAK-881

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q1 2029

Trials by Indication[1]

Adult2 trials

Immunodeficiency Disease2 trials

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1 trial

Primary Immunodeficiency Diseases1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News